Current trends in the pharmacologic and surgical treatment of Parkinson's disease.
Recently, there has been a surge in the research regarding the pharmacologic and surgical treatment of Parkinson's disease. This article reviews the latest modes of medical and surgical therapy for Parkinson's disease. The latest drug therapy has consisted of levodopa, a combination of levodopa and carbidopa (Sinemet/Sinemet CR), and monoamine oxidase type B (MAO-B) inhibitors (selegiline hydrochloride). The surgical treatment modalities have been stereotaxic implantations of dopamine-producing tissues (such as adrenal medulla and fetal mesencephalon) into the caudate nucleus and ventral pallidotomy of patients with Parkinson's disease. The most recent work has been in the field of gene therapy. The implantation of cells genetically modified to express trophic factors and tyrosine hydroxylase for the synthesis of L-dopa from tyrosine has been proposed as a possible route for the treatment of Parkinson's disease. Although the etiology of the disease is still unknown, two recent theories are discussed.
Galler
R M
RM
Department of Neurology and Neuroscience, New York College of Osteopathic Medicine of New York Institute of Technology, Old Westbury, USA.
Hallas
B H
BH
Fazzini
E
E
D002986:Clinical Trials as Topic; D004358:Drug Therapy / Q000639:trends; D015316:Genetic Therapy / Q000639:trends; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D011379:Prognosis; D013514:Surgical Procedures, Operative / Q000639:trends